Clinical Trial Finder

Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for enrollment as study participants: 1. Age 18 years or older. 2. Classification of Systemic Lupus Erythematosus (SLE) by any of the following criteria: the 1997 update of the 1982 American College of Rheumatology (ACR) criteria, the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria, or the 2019 European League Against Rheumatism (EULAR)/ACR criteria. 3. UPCR ≥ 1.0 based on a 24-hour urine collection at Visit -1 or within 14 days prior to Visit -1. 4. Renal biopsy within 24 weeks prior to Visit -1 of ISN/RPS LN with both of the following: 1. Class III, Class IV, or Class V in combination with Class III or IV, and. 2. Modified NIH Activity Index ≥ 1.

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study participants: 1. Inability or unwillingness to give written informed consent or comply with study protocol. 2. Contraindication to treatment with MMF or mycophenolate sodium; or treatment with MMF or mycophenolate sodium is inappropriate in the opinion of the investigator. 3. Treatment with a biologic agent, except belimumab, or investigational agent within 90 days or 5 half-lives prior to Visit 0, whichever is longer. 4. Rituximab or other B cell depleting agent within 6 months prior to Visit 0. 5. Prior treatment with VIB4920. 6. Receipt of a live attenuated vaccine within 4 weeks prior to Visit 0. 7. Comorbidities requiring treatment with systemic corticosteroids, including those that have required 3 or more courses of systemic corticosteroids within 12 months prior to Visit 0. 8. Current malignancy or history of malignancy, except for adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ > 12 months prior to Visit 0. 9. ESRD, defined as eGFR < 20 ml/min/1.73m2. 10. History of transplantation. 11. The following risks for thromboembolic events: 1. Recent or recurrent deep venous thrombosis or arterial thromboembolism. 2. Immobilization or major surgery within 12 weeks prior to Visit 0. 3. History of congenital or inherited deficiency of antithrombin III, protein S, or protein C. 4. History of anti-phospholipid syndrome, according to the 2006 Sapporo classification criteria. 12. History of a severe allergy or hypersensitivity reaction to any component of the VIB4920 formulation. 13. Any one of the following laboratory abnormalities: 1. Peripheral B cell count < 5/μl. 2. Neutropenia (absolute neutrophil count < 1000/mm3). 3. Anemia (hemoglobin < 8 g/dL). 4. Thrombocytopenia (platelets < 50,000/mm3). 5. Aspartate aminiotransferase or alanine aminotransferase ≥ 2x upper limit of normal. 14. Evidence of current or prior tuberculosis infection, including any of the following: 1. Positive QuantiFERON-TB Gold or TB Gold Plus test. 2. Positive T-SPOT.TB test. 3. Positive purified protein derivation (PPD) tuberculin test, defined as > 5mm induration. 15. Human immunodeficiency virus (HIV) infection. 16. Current or past hepatitis B (HBV) infection. 17. Current or past hepatitis C virus (HCV) infection, except adequately treated HCV with documented sustained virologic response. 18. Active bacterial, viral, fungal, or opportunistic infection. 19. History of significant, recurrent, or chronic infection that may pose additional risks from participating in the study, in the opinion of the investigator. 20. History of severe psychiatric condition that would interfere with the participant's ability to comply with the study protocol, in the opinion of the investigator. 21. Current substance abuse, or history of substance abuse within 12 months of Visit 0. 22. Lack of peripheral venous access. 23. Pregnancy. 24. Breastfeeding. 25. Unwillingness to use a medically acceptable form of contraception for the duration of the study if female of child-bearing potential or if male with a partner of childbearing potential. 26. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Seventy-four eligible participants with active lupus nephritis (LN) will be randomized to receive VIB4920 1500 mg or placebo intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24. Participants will receive a total of 1000 mg of methylprednisolone according to either of the following schedules:

• - 1000 mg methylprednisolone IV at Day 0, or.

• - 500 mg methylprednisolone IV at Day 0 and at Day 1.

Participants who previously received 1000 mg of methylprednisolone IV within 42 days of Visit 0 will not receive additional methylprednisolone IV on Day 0. Participants who previously received less than 1000 mg of methylprednisolone IV within 42 days of Visit 0 will receive an additional dose of methylprednisolone IV at Day 0, according to the following formula, where X is the intravenous dose previously received and Y is the intravenous dose administered on Day 0: 1000 mg

• - X = Y.

Participants will also receive MMF 2-3 g per day and will receive prednisone 25 mg/d beginning on Day 0, or on the day after completion of methylprednisolone. Prednisone will be tapered to 5 mg/d by Week 8.

Arms

Experimental: VIB4920

Participants will receive VIB4920 1500 mg intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24. Participants who previously received 1000 mg of methylprednisolone IV within 42 days of Visit 0 will not receive additional methylprednisolone IV on Day 0. Participants who previously received less than 1000 mg of methylprednisolone IV within 42 days of Visit 0 will receive an additional dose of methylprednisolone IV at Day 0, according to the following formula, where X is the intravenous dose previously received and Y is the intravenous dose administered on Day 0: 1000 mg - X = Y. Participants will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to 5 mg per day by Week 8. The prednisone dose may be tapered more rapidly and to a dose lower than 5 mg/d, at the discretion of the site investigator. Prednisone of no more than 5 mg/d will be continued until Week 60.

Placebo Comparator: VIB4920 Placebo

Participants will receive VIB4920 placebo intravenously at Weeks 0, 2, 4, 8, 12, 16, 20, and 24. Participants who previously received 1000 mg of methylprednisolone IV within 42 days of Visit 0 will not receive additional methylprednisolone IV on Day 0. Participants who previously received less than 1000 mg of methylprednisolone IV within 42 days of Visit 0 will receive an additional dose of methylprednisolone IV at Day 0, according to the following formula, where X is the intravenous dose previously received and Y is the intravenous dose administered on Day 0: 1000 mg - X = Y. Participants will begin MMF 2-3 g per day and prednisone 25 mg per day, tapered to 5 mg per day by Week 8. The prednisone dose may be tapered more rapidly and to a dose lower than 5 mg/d, at the discretion of the site investigator. Prednisone of no more than 5 mg/d will be continued until Week 60.

Interventions

Drug: - VIB4920

Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone

Drug: - Placebo for VIB4920

Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone